Fusion Antibodies PLC Ordinary Shares (FAB)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

16.00p

Buy

16.50p

arrow-down-0.54p (-3.09%)

Prices updated at 16 Dec 2025, 14:56 GMT

Prices minimum 15 mins delay

Prices in GBX

Fusion Antibodies PLC is engaged in the research, development and manufacturing of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases.

FTSE All-Share

-0.66%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Simon Gordon Douglas

CEO

Dr. Adrian Robert Kinkaid

Most recent earnings

31 Mar 2025

Fiscal year end

31 Mar 2025

Employees

18

Head office

1 Springbank Road

Belfast

United Kingdom

BT17 0QL

+44 2079338780

info@fusionantibodies.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Simon Gordon Douglas Non-Executive Director, Chairman	-
Mr. Colin James Walsh Non-Executive Director	-
Mr. Matthew Paul Baker Non-Executive Director	-
Dr. Richard John Buick Executive Director, Chief Scientific Officer	-
Dr. Adrian Robert Kinkaid Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Unicorn Asset Management Ltd	6,397,290
Unicorn AIM VCT Series 3 ORD	6,397,290
Octopus Investments Limited	870,968
Hargreave Hale Limited	544,311
Hargreave Hale AIM VCT	544,311

Director dealings

Date chevron-l-regular chevron-r-regular	Action
07 Jul 2025	Transfer in
07 Jul 2025	Transfer in
12 May 2025	Purchase
12 May 2025	Purchase
12 May 2025	Purchase
06 May 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.